Seneca Biopharmaceuticals, Inc. is focused on finding promising new science and developing a pipeline of biopharmaceuticals.

Seneca Biopharmaceuticals, Inc.

Seneca Therapeutics, Inc. | 450 followers on LinkedIn. Seneca Therapeutics is developing a novel cancer therapy (oncolytic immunotherapeutic) for patients with solid cancers | Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus.  SVV-001 is already in Phase I/II and has a clinical safety record in humans.

Founder, President and Chief Scientific Officer at Seneca Therapeutics, Inc.

Paul Hallenbeck

Board Member, Finance Advisory Committee Member, Corporate Advisor

Mark Kerschner

Chief Executive Officer at Seneca Therapeutics, Inc.

James Hussey

Human Resources and Business Operations Manager at Seneca Therapeutics, Inc

Janice Ingram

Seneca Therapeutics, Inc.

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics, Presented at Oncolytic Virus Conference on December 13th

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics Presented at Oncolytic Virus Conference on December 13th https://buff.ly/41zd97x

Seneca Therapeutics CSO and President Dr Paul Hallenbeck will present on December 13 at the 5th Annual Oncolytic Virotherapy Summit 2023. The talk is titled "Assessing the Benefits and Challenges of Intravenous Delivery pf Oncolytic Viruses". His talk will include the characteristics needed to delivery multiple doses of oncolytic viruses. He will also share the latest updates regarding TEM8, ANTXR1 and SVV-001. #ANTXR1 #TEM8 #SVV001 #OVmultipleIV

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at World Vaccine Congress November 28, 2023 https://buff.ly/40YCmIb

Seneca Therapeutics to Present Talk at World Vaccine Congress titled "Facilitating multiple deliveries of therapeutics vaccines by exploiting natural methods of evading neutralizing immunity" Seneca Therapeutics has continued to discover new and important features of Seneca Valley Virus (SVV-001). Dr. Paul Hallenbeck, Chief Science Officer and President at Seneca Therapeutics is presenting at the World Vaccine Congress on November 28, 2023. The title of the presentation is “Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity”. Using Seneca Therapeutics patented SVV-001 Gene Library and DNA Launch technology, the company discovered several biologically active SVV-001 mutants which evade neutralizing antibodies from prior SVV-001 exposure. (SVV-nabev (neutralizing antibody evading)). Three mutants have been discovered which will permit six IV doses of SVV-001 over three months. Following the results of the Phase I/II trial with multiple IT dosing in SVV-001 sensitive neuroendocrine tumors, the company plans on bringing at least three SVV-nabev candidates for a single IV dosage regimen into the clinic. SVV-001 has been shown to be safe as a single IV dose demonstrating excellent cancer selectivity. SVV-001 single IV dosing also demonstrated preliminary monotherapy efficacy against neuroendocrine tumors. Seneca Therapeutics has two other approaches for administering multiple IV doses of SVV-001 in development. #multipleIVdeliveryofcancerviruses #senecatherapeutics #TEM8tumormarker #SVV001 #cancervirusbreakthrough

SENE

COM:SENECABIO

Seneca Biopharmaceuticals, Inc.